A non-brain penetrant PDE5A inhibitor improves functional recovery after stroke in rats

Restorative Neurology and Neuroscience

Volumn 30, Issue 4, 2012, Pages 283-289

  Menniti, Frank S ^a   Ren, Jingmei ^b   Sietsma, Dana K ^b   Som, Angel ^b   Nelson, Fredrick R ^a   Stephenson, Diane T ^a   Tate, Barbara A ^a   Finklestein, Seth P ^b  

^a PFIZER INC   (United States)

^b Biotrofix   (United States)

Author keywords

brain penetration; PDE5A; PF 489,791; PF 5; Phosphodiesterase 5A; stroke recovery

Indexed keywords

3 [4 (2 HYDROXYETHYL)PIPERAZIN 1 YL] 7 (6 METHOXYPYRIDIN 3 YL) 1 (2 PROPOXYETHYL)PYRIDO[3,4 B]PYRAZIN 2(1H) ONE; PF 489791; PF 5; PHOPHODIESTERASE 5A INHIBITOR; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BODY MOVEMENT; CONVALESCENCE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG PENETRATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR PERFORMANCE; NONHUMAN; PRIORITY JOURNAL; RAT; STROKE;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PHOSPHODIESTERASE 5 INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; STROKE; TIME FACTORS;

EID: 84863937258     PISSN: 09226028     EISSN: 18783627     Source Type: Journal    
DOI: 10.3233/RNN-2012-110187     Document Type: Article

References (35)

1. Bednar, M. (2008). The role of sildenafil in the treatment of stroke. Curr Opin Invest Drugs, 9(7), 754-759.
2. Borlongan, C.V., Hida, H.&Nishino, H. (1998). Early assessment of motor dysfunctions aids in successful occlusion of the middle cerebral artery. NeuroRep 9(16), 3615-3621.
3. Borlongan, C.V. & Sanberg, P.R. (1995). Elevated body swing test: A new behavioral parameter for rats with 6- hydroxydopamineinduced hemiparkinsonism. J Neurosci, 15(7), 5372-5378.
4. Carmichael, S.T. (2006). Cellular and molecular mechanisms of neural repair after stroke: Making waves. Ann Neurol, 59(5), 735-742.
5. Chen, J. & Chopp, M. (2006). Neurorestorative treatment of stroke: Cell and pharmacological approaches. NeuroRX, 3(4), 466-473.
6. Cramer, S.C., Koroshetz, W.J. & Finklestein, S.P. (2007). The case for modality-Specific outcome measures in clinical trials of stroke recovery-Promoting agents. Stroke, 38(4), 1393-1395.
7. Ding, G., Jiang, Q., Li, L., Zhang, L., Zhang, Z.G., Ledbetter, K.A., Panda, S., Davarani, S.P., Athiraman, H., Li, Q., Ewing, J.R. & Chopp, M. (2008). Magnetic resonance imaging investigation of axonal remodeling and angiogenesis after embolic stroke in sildenafil-Treated rats. J Cereb Blood Flow Met, 28(8), 1440-1448.
8. Dombovy, M. (2004). Understanding stroke recovery and rehabilitation: Current and emerging approaches. Curr Neurolog Neurosci Reports, 4(1), 31-35.
9. Fisher,M.&Ratan, R. (2003). Newperspectives on developing acute stroke therapy. Ann Neurol, 53(1), 10-20.
10. Giordano, D., De Stefano, M.E., Citro, G., Modica, A. & Giorgi, M. (2001). Expression of cGMP-Binding cGMP-Specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-Terminal domain. Biochim Biophys Acta, 1539(1-2), 16-27.
11. Green, AR. (2008) Pharmacological approaches to acute ischaemic stroke: Reperfusion certainly, neuroprotection possibly. Br J Pharmacol 153(Suppl 1) S325-338
12. Hemnes, A.&Champion, H. (2006). Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypert. Expert Rev Cardiovas Ther, 4(3), 293-300.
13. Hitchcock, S.A. & Pennington, L.D. (2006). Structure-Brain exposure relationships. J Med Chem, 49(26), 7559-7583.
14. Hughes, R.O., Rogier, D.J., Jacobsen, E.J., Walker, J.K., MacInnes, A., Bond, B.R., Zhang, L.L., Yu, Y., Zheng, Y., Rumsey, J.M., Walgren, J.L., Curtiss, S.W., Fobian, Y.M., Heasley, S.E., Cubbage, J.W., Moon, J.B., Brown, D.L., Acker, B.A., Maddux, T.M., Tollefson, M.B., Mischke, B.V., Owen, D.R., Freskos, J.N., Molyneaux, J.M., Benson, A.G. & Blevis-Bal, R.M. (2010). Design, synthesis, and biological evaluation of 3-[4- (2-Hydroxyethyl)piperazin- 1-yl]-7-(6-Methoxypyridin-3-yl)- 1-(2-Propoxyethyl)pyrido[3,4-B]pyrazin-2(1H)- one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5). J Med Chem, 53(6), 2656-2660.
15. Kalra, L. & Ratan, R. (2007). Recent advances in stroke rehabilitation 2006. Stroke, 38(2), 235-237.
16. Kass, D.A., Champion, H.C. & Beavo, J.A. (2007). Phosphodiesterase type 5: Expanding roles in cardiovascular regulation. Circ Res, 101(11), 1084-1095.
17. Kotera, J., Fujishige, K. & Omori, K. (2000). Immunohistochemical localization of cGMP-Binding cGMP-Specific phosphodiesterase (PDE5) in rat tissues. J Histochem Cytochem, 48(5), 685-693.
18. Kruse, L.S., Sandholdt, N.T., Gammeltoft, S., Olesen, J. & Kruuse, C. (2006). Phosphodiesterase 3 and 5 and cyclic nucleotidegated ion channel expression in rat trigeminovascular system. Neurosci Lett, 404(1-2), 202-207.
19. Li, L., Jiang, Q., Zhang, L., Ding, G., Gang Zhang, Z., Li, Q., Ewing, J.R., Lu, M., Panda, S., Ledbetter, K.A., Whitton, P.A.&Chopp, M. (2007). Angiogenesis and improved cerebral blood flow in the ischemic boundary area detected by MRI after administration of sildenafil to rats with embolic stroke. Brain Res, 1132, 185-192.
20. McAllister-Lucas, L.M., Haik, T.L., Colbran, J.L., Sonnenburg, W.K., Seger, D., Turko, I.V., Beavo, J.A., Francis, S.H. & Corbin, J.D. (1995). An essential aspartic acid at each of two allosteric cGMP-Binding sites of a cGMP-Specific phosphodiesterase. J Biol Chem, 270(51), 30671-30679.
21. Menniti, F., Ren, J., Coskran, T., Liu, J., Morton, D., Sietsma, D., Som, A., Stephenson, D., Tate, B. & Finklestein, S. (2009). PDE5A inhibitors improve functional recovery after stroke in rats: Optimized dosing regimen and implications for mechanism. J Pharmacol Exp Ther, 331(3), 1-9.
22. Nakamizo, T., Kawamata, J., Yoshida, K., Kawai, Y., Kanki, R., Sawada, H., Kihara, T., Yamashita, H., Shibasaki, H., Akaike, A. & Shimohama, S. (2003). Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons. J Neurosci Res, 71(4), 485-495.
23. Ren, J.M. & Finklestein, S.P. (2005). Growth factor treatment of stroke. Current Drug Targets-CNS & Neurological Disorders, 4, 121-125.
24. Sandner, P., Svenstrup, N., Tinel, H., Haning, H. & Bischoff, E. (2008). Phosphodiesterase 5 inhibitors and erectile dysfunction. Exp Opin Ther Pat, 18(1), 21-33.
25. Schallert, T., Fleming, S.M., Leasure, J.L., Tillerson, J.L. & Bland, S.T. (2000). CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacol, 39(5), 777-787.
26. Shaffer, C.L. (2010). Defining neuropharmacokinetic parameters in CNS drug discovery to determine cross-Species pharmacologic exposure-Response relationships. Ann Rep Med Chem, 45, 55-70.
27. Shimizu-Albergine, M., Rybalkin, S.D., Rybalkina, I.G., Feil, R., Wolfsgruber,W., Hofmann, F.&Beavo, J.A. (2003). Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): In vivo phosphorylation of cGMP-Specific PDE (PDE5) as an indicator of cGMP-Dependent protein kinase (PKG) activation. J Neurosci, 23(16), 6452-6459.
28. Tamura, A., Graham, D., McCulloch, J.&Teasdale, G. (1981). Focal cerebral ischemia in the rat: 1. Description of technique and early neuropathological. J Cereb Blood Flow Metab, 1, 53-60.
29. The National Institute of Neurological Disorders Stroke rtPA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med, 333(24) 1581-1588.
30. Weintraub, M.I. (2006). Thrombolysis (tissue plasminogen activator) in stroke: A medicolegal quagmire. Stroke, 37(7), 1917-1922.
31. Wolk, R., Smith,W.B., Neutel, J.M., Rubino, J., Xuan, D., Mancuso, J., Gilbert, J. & Pressler,M.L. (2009). Blood pressure lowering effects of a new long-Acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension. Hypertension, 53(6), 1091-1097.
32. Xiong, Y., Mahmood, A. & Chopp, M. (2010). Angiogenesis, neurogenesis and brain recovery of function following injury. Curr Opin Invest Drugs, 11(3), 298-308.
33. Zhang, L., Zhang, R.L.,Wang, Y., Zhang, C., Zhang, Z.G., Meng, H. & Chopp, M. (2005b). Functional recovery in aged and young rats after embolic stroke: Treatment with a phosphodiesterase type 5 inhibitor. Stroke, 36(4), 847-852.
34. Zhang, L., Zhang, Z., Zhang, R.L., Cui,Y., LaPointe, M.C., Silver,B. &Chopp, M. (2006). Tadalafil, a long-Acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Res, 1118(1), 192-198.
35. Zhang, R.,Wang,Y., Zhang, L., Zhang, Z., Tsang,W., Lu, M., Zhang, L. & Chopp, M. (2002). Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke, 33(11), 2675-2680.